Clinical trials: Recurrent Head and Neck Carcinoma
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma of the Head and Neck
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
The primary objective of this study was to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with recurrent or metastatic…
- Trial name
- MASTERKEY232 (NCT02626000)
- Testing
- Talimogene Laherparepvec, Pembrolizumab
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well bortezomib works in treating patients with metastatic thyroid cancer that did not respond to radioactive iodine therapy.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00104871
- Testing
- Bortezomib
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Head and Neck
SHR-1701 in Patients With Recurrent/Metastatic Scchn
This is an open label, single-arm, multi-center, phase II study of SHR-1701 in patients with recurrent/metastatic SCCHN
- Trial name
- NCT04650633
- Testing
- SHR-1701
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Head and Neck Cancer
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.
- Trial name
- NCT04313504
- Testing
- Niraparib, Dostarlimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Trisha Wise-Draper
Head and Neck Cancer
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004163
- Testing
- Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma of Head and Neck
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
Subjects will receive treatment with nivolumab monotherapy at 240mg flat dose as a 30 minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death…
- Trial name
- NIVACTOR (NCT05802290)
- Testing
- Nivolumab 240 MG in 24 ML Injection
- Where
- 23 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
This study is evaluating INCB081776 when given in combination with the checkpoint inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or recurrent metastatic or recurrent head and neck squamous…
- Trial name
- NCT06308913
- Testing
- INCB081776, Pembrolizumab, Palliative RT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Wisconsin, Madison
Recurrent Head and Neck Carcinoma
Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer
This pilot clinical trial studies cesium Cs 131 brachytherapy in treating patients with head and neck cancer that has come back (recurrent) and can be removed by surgery.
- Trial name
- NCT02467738
- Testing
- Brachytherapy, Cesium-131, Conventional surgery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05172258
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 20 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248560
- Testing
- docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)
Study Objective: Primary 1. To evaluate the complete response (CR) rate with induction chemotherapy using Docetaxel, Cisplatin and Fluorouracil(TPF) followed by Docetaxel plus Cetuximab (TC) in concurrence with…
- Trial name
- NCT01326559
- Testing
- Docetaxel, Cisplatin, 5-FU and Cetuximab
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Hong Kong Nasopharyngeal Cancer Study Group Limited
Head & Neck Squamous Cell Carcinoma
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
phase II, randomized, double-blind, placebo controlled, non pharmacological clinical trial that aims to determine the effect of postbiotics Postbiotix-HLA™ on immuno-related adverse events (irAEs) in patients with…
- Trial name
- POST-BIO (NCT07485296)
- Testing
- Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., Pembolizumab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Esophageal Cancer, Recurrence
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor.
- Conditions
- Esophageal Cancer, Recurrence, DNA Methylation
- Trial name
- NCT06476067
- Testing
- Surgery
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- City of Hope Medical Center
SCCHN
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous cell carcinoma of the head…
- Trial name
- NCT03771820
- Testing
- NC-6004, Pembrolizumab
- Where
- 24 sites in Croatia, Czechia and 6 more
- Volunteers
- 136 people
- Sponsor
- NanoCarrier Co., Ltd.
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
This phase II trial studies how well cemiplimab works before surgery in treating patients with stage II-IV head and neck cutaneous squamous cell cancer that has come back (recurrent) and can be removed by surgery (resectable).
- Conditions
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT03565783
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
HNSCC
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with…
- Trial name
- PEMDA-HN (NCT05814666)
- Testing
- Danvatirsen, Pembrolizumab
- Where
- 32 sites in United States, South Korea and 1 more
- Volunteers
- 69 people
- Sponsor
- Flamingo Therapeutics NV
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different…
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06678724
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.